The Progressive Corporation reported financial results for the month ended August 31, 2026, with net income of $951 million ($1.63 per share) on net premiums earned of $7.35 billion. The company's combined ratio for the month was 89.3, and total policies in force grew 7% year-over-year to 40.5 million.
BlossomHill Therapeutics reported financial results for the second quarter of 2026, highlighting the successful completion of its $168.3 million IPO in August. The company also noted clinical progress for BH-30643, which received FDA Fast Track designation for the treatment of advanced EGFR C797S-positive NSCLC.
Term
Q2 2026
“We’ve achieved meaningful progress across our pipeline, as well as our significant corporate milestones, since the beginning of the second quarter. In April, we presented our first preclinical data from our pseudo-irreversible pan-KRAS inhibitor BH-501284, built on a novel chemical scaffold, at AACR where we highlighted the sustained target engagement leading to tumor regression at low dose levels.”
Jean Cui, Ph.D., Founder, President and Chief Executive Officer
“With a strong balance sheet following our successful initial public offering in August, we believe we are well positioned to deliver important clinical and regulatory milestones over the coming quarters as we continue advancing our intentionally designed medicines that address significant unmet medical needs in cancer treatment.”
Jean Cui, Ph.D., Founder, President and Chief Executive Officer